Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (371-380 of 645) with videos related to

Pageof 65
Sort By:
American Journal of Respiratory Cell and Molecular Biology|July 23, 2016
Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial HyperresponsivenessPaola Rogliani, Luigino Calzetta, Barbara Capuani, et al.
Respiratory Medicine|May 22, 2021
Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patientsMauro Maniscalco, Salvatore Fuschillo, Pasquale Ambrosino, et al.
European Journal of Pharmacology|May 9, 2015
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiPaola Rogliani, Luigino Calzetta, Josuel Ora, et al.
Respiratory Medicine|November 18, 2005
Respiratory infections and asthmaGirolamo Pelaia, Alessandro Vatrella, Luca Gallelli, et al.
Pulmonary Pharmacology & Therapeutics|May 9, 2015
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)Fulvio Braido, Giovanni Melioli, Mario Cazzola, et al.
Drugs|July 23, 2025
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation PerspectiveMario Cazzola, Clive P Page, Luigino Calzetta, et al.
Respiratory Research|February 28, 2024
The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitroMaria Gabriella Matera, Barbara Rinaldi, Cecilia Calabrese, et al.
Pulmonary Pharmacology & Therapeutics|April 3, 2003
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol TurbuhalerMario Cazzola, Maria Gabriella Matera, Maria D'Amato, et al.
Respiration; International Review of Thoracic Diseases|March 20, 2004
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPDMario Cazzola, Maria Gabriella Matera, Paolo Ruggeri, et al.
Respiratory Medicine|April 19, 2021
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitationMauro Maniscalco, Pasquale Ambrosino, Salvatore Fuschillo, et al.
Pageof 65

Showing results (371-380 of 645) with videos related to

Sort By:
Pageof 65
American Journal of Respiratory Cell and Molecular Biology|July 23, 2016
Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial HyperresponsivenessPaola Rogliani, Luigino Calzetta, Barbara Capuani, et al.
Respiratory Medicine|May 22, 2021
Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patientsMauro Maniscalco, Salvatore Fuschillo, Pasquale Ambrosino, et al.
European Journal of Pharmacology|May 9, 2015
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiPaola Rogliani, Luigino Calzetta, Josuel Ora, et al.
Respiratory Medicine|November 18, 2005
Respiratory infections and asthmaGirolamo Pelaia, Alessandro Vatrella, Luca Gallelli, et al.
Pulmonary Pharmacology & Therapeutics|May 9, 2015
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation)Fulvio Braido, Giovanni Melioli, Mario Cazzola, et al.
Drugs|July 23, 2025
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation PerspectiveMario Cazzola, Clive P Page, Luigino Calzetta, et al.
Respiratory Research|February 28, 2024
The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitroMaria Gabriella Matera, Barbara Rinaldi, Cecilia Calabrese, et al.
Pulmonary Pharmacology & Therapeutics|April 3, 2003
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol TurbuhalerMario Cazzola, Maria Gabriella Matera, Maria D'Amato, et al.
Respiration; International Review of Thoracic Diseases|March 20, 2004
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPDMario Cazzola, Maria Gabriella Matera, Paolo Ruggeri, et al.
Respiratory Medicine|April 19, 2021
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitationMauro Maniscalco, Pasquale Ambrosino, Salvatore Fuschillo, et al.
Pageof 65